TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Abolition of global venous reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in VCSS, AVVQ, and STS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: any stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: disabling stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: PAH activity of the whole liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Enamel loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-specific HRQoL of older patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Generic mental HRQoL of older patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Generic mental HRQoL of male patients
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak plasma concentration of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of peak concentration of ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transfusion requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: thrombocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: endurance time during cycling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnoea and mastery of daily living activities
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: average relief duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained viral response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: body-image scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum levels of MCP‐1 and sVCAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL‐6 and TNF‐alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of vascular events
Endpoint domain: Mortality/survival
Primary endpoint: anterior chamber inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: intraocular pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Adequate levels of gist understanding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adequate levels of verbatim understanding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: tumour necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: tumour recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Postoperative control of prolapse symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ashworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual Faces Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Kurtzke Disability Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with differential block
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensory block achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maintenance of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in clinical scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of skin histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: PGM changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal passive dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal passive resistive force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stored passive-elastic energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aortic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart failure readmission or all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Hepatitis B vaccination coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WCC visit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive decline measured by Alzheimer's Disease Assessment Scale-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: lymphocyte recovery ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: donation intention
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ET-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dermal abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Erythema or edema
Endpoint domain: Adverse events/effects
Primary endpoint: Pain/discomfort associated with IDDS delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Local skin tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Adhesion of transdermal system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Molidustat AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molidustat Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPO AUC(0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased symptom days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased caregiver daily life stress
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: No-show rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dementia Rating Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WMS‐III Logical Memory I scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WMS‐III Logical Memory II scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eosinophil levels in the nasal epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Basophil levels in the nasal epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of intraocular hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: younger appearance rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Indices of the homogeneity of repolarization (PCA‐T, E1‐T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin sensitivity to egg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MENQOL overall score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MENQOL vasomotor domain score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: clinical volume augmentation of deficient papillae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incident knee OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Correct identification of sham
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body peristaltic amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Latency of esophageal peristalsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Likelihood of obtaining a diagnostic sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in DLQI total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall disability rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of cerebral palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: prevention of viral shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Contribution to mortality
Endpoint domain: Mortality/survival
Primary endpoint: leaks/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of urgency/24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean voided volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and salivary IgG levels against vaccine serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Need for antihyperglycemic drug therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: complete clearing of the treated wart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet reactivity during PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total crying reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colicky crying reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of facial basal cell carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cure rate of truncal basal cell carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in urogenital symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Vaginal health score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incident cardiovascular disease (CVD) events
Endpoint domain: Mortality/survival
Primary endpoint: Pain scores during biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embolic events during total knee arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retention in pre-ARV care
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: daily body weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: global preventive service delivery rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean clinical quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient experience score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Transformation to normal Chinese medical syndrome type
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of IFN-gamma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IFN-gamma/IL-4 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: auditory recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of 8‐iso‐prostaglandin F2alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary excretion of 11‐dehydro‐thromboxane B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tDCS effects on PASSMA→M1 induced plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major interest in sex
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of sleep time with snoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of SCS versus reoperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haze reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functional capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic progression of RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of UV-induced erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: DHRQOL improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall diabetes burden decline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean infection scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: wound reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude of motor memory formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responses to acetylcholine (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urea levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aspartate transaminase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hsPDA closure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T-lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Surgical failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of VOD (veno-occlusive disease)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete response for dysplasia in LGD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response for dysplasia in HGD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change of the radial artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with pre-UDS counseling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time for treatment completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in level of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of left atrial thrombi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of left atrial dense spontaneous echo contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PAP therapy adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleepiness (Epworth Sleepiness Scale)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in cumulative visual field total point score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of vision-impairing diabetic macular edema
Endpoint domain: Adverse events/effects
Primary endpoint: Cost incurred by the patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: breast engorgement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: breastfeeding practices
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction of HAMD-17 score ≥ 20% within the first 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant difference in HAMD-17 and MADRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-concept differences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thromboxane B2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Group C meningococcal immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: gas retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: abdominal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: household smoking bans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained quitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of rhythm disturbances
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postoperative arrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of newly developed atrioventricular block
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants reporting abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in MADRS at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regained pre-injury mobility status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission rates
Endpoint domain: Mortality/survival
Primary endpoint: Clinically significant POPF
Endpoint domain: Adverse events/effects
Primary endpoint: Unbound AUC0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration in vivo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival rates at 28 and 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Final height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ETT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of mean arterial blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in CTS symptom severity scores at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of surgery at 1 year
Endpoint domain: Adverse events/effects
Primary endpoint: HIV-RNA < 500 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4 cell changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative efficacy of a second dose of IVIG compared to infliximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient/parent experience of treatments
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of skin manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximal improvements in disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fast onset of clinically-meaningful effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Duration of effect up to Weeks 12-20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Apolipoprotein A1 (ApoA1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ubiquinol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum cysC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes